Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Positive airway pressure therapy
21 evidence topics · 14 sources
VA/DoD guideline: evidence cutoff date for the 2025 recommendations
VA/DoD guideline: mandibular advancement devices, PAP, or surgical referral (strong for)
VA/DoD guideline algorithm: PAP as first-line therapy for severe OSA
VA/DoD guideline: auto-titrating over fixed CPAP at initiation (weak for)
VA/DoD guideline: educational, behavioral, and supportive interventions to improve PAP usage (weak for)
VA/DoD guideline: PAP effects on symptoms, cardiovascular outcomes, and side effects
AASM guideline: PAP for excessive sleepiness (strong), impaired sleep-related quality of life (conditional), and comorbid hypertension (conditional)
“Recommendation 1: We recommend that clinicians use positive airway pressure, compared to no therapy, to treat OSA in adults with excessive sleepiness. (STRONG)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The TF identified 38 randomized controlled trials (RCTs) that assessed the efficacy of PAP to reduce excessive sleepiness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation 2: We suggest that clinicians use positive airway pressure, compared to no therapy, to treat OSA in adults with impaired sleep-related quality of life. (CONDITIONAL)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation 3: We suggest that clinicians use positive airway pressure, compared to no therapy, to treat OSA in adults with comorbid hypertension. (CONDITIONAL)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This clinical practice guideline reflects the state of knowledge at the time of publication and will be reviewed and updated as new information becomes available.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AASM guideline: PAP initiation, modality, and adherence interventions
“Recommendation 4: We recommend positive airway pressure therapy be initiated using either APAP at home or in-laboratory PAP titration in adults with OSA and no significant comorbidities. (STRONG)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation 5: We recommend that clinicians use either APAP or CPAP for ongoing treatment of OSA in adults. (STRONG)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation 6: We suggest that clinicians use CPAP or APAP over BPAP in the routine treatment of OSA in adults. (CONDITIONAL)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation 7: We recommend that educational interventions be given prior to initiation of PAP therapy in adults with OSA. (STRONG)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Recommendation 9: We suggest that clinicians use telemonitoring-guided interventions during the initial period of PAP therapy in adults with OSA. (CONDITIONAL)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
AASM guideline: no recommendation on PAP to reduce cardiovascular events in non-sleepy adults
“There is insufficient and inconclusive evidence to either recommend or withhold PAP to treat non-sleepy adults with OSA as a means to reduce cardiovascular events or mortality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Meta-analyses of observational studies suggested a reduction in CV events and mortality with PAP therapy. In contrast, meta-analyses of randomized controlled trials demonstrated no clinically significant improvements in CV events or mortality.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
ACP guideline: CPAP as initial therapy (strong recommendation, moderate-quality evidence)
“This guideline is based on published literature from 1966 to September 2010 that was identified by using MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“RECOMMENDATION 2: ACP recommends continuous positive airway pressure treatment as initial therapy for patients diagnosed with OSA. (Grade: strong recommendation; moderate-quality evidence)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
SAVE: CPAP and cardiovascular events in OSA with established cardiovascular disease, OSA defined by a 4% oxygen desaturation index of at least 12
ISAACC: CPAP and cardiovascular events after acute coronary syndrome in non-sleepy participants
“The prevalence of cardiovascular events was similar in the CPAP and UC groups (98 events [16%] vs 108 events [17%]; hazard ratio [HR] 0·89 [95% CI 0·68-1·17]; p=0·40) during follow-up.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Mean time of adherence to CPAP treatment was 2·78 h/night (SD 2·73).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Among non-sleepy patients with ACS, the presence of OSA was not associated with an increased prevalence of cardiovascular events and treatment with CPAP did not significantly reduce this prevalence.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
RICCADSA: CPAP in coronary artery disease with non-sleepy OSA, AHI of at least 15 per hour, hypopnea scoring rule not stated in the abstract
“Consecutive patients with newly revascularized CAD and OSA (apnea-hypopnea index ≥15/h) without daytime sleepiness (Epworth Sleepiness Scale score <10) were randomized to auto-titrating CPAP (n = 122) or no positive airway pressure (n = 122).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence of the primary endpoint did not differ significantly in patients who did versus did not receive CPAP (18.1% vs. 22.1%; hazard ratio, 0.80; 95% confidence interval, 0.46-1.41; P = 0.449).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Adjusted on-treatment analysis showed a significant cardiovascular risk reduction in those who used CPAP for ≥4 versus <4 hours per night or did not receive treatment (hazard ratio, 0.29; 95% confidence interval, 0.10-0.86; P = 0.026).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
CPAP and incident hypertension or cardiovascular events in non-sleepy OSA, AHI of at least 20 per hour, hypopnea scoring rule not stated in the abstract
“Between May 2004 and May 2006, 725 consecutive patients were enrolled who had an apnea-hypopnea index of 20 h(-1) or greater and an Epworth Sleepiness Scale score of 10 or less (scores range from 0-24, with values <10 suggesting no daytime sleepiness).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The incidence density ratio was 0.83 (95% CI, 0.63-1.1; P = .20).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In patients with OSA without daytime sleepiness, the prescription of CPAP compared with usual care did not result in a statistically significant reduction in the incidence of hypertension or cardiovascular events. However, the study may have had limited power to detect a significant difference.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Individual participant data meta-analysis of SAVE, ISAACC, and RICCADSA: intention-to-treat and adherent CPAP use
“The main outcome was defined as the first MACCE, which was similar for the CPAP and no CPAP groups (hazard ratio, 1.01 [95% CI, 0.87-1.17]). However, an on-treatment analysis by marginal structural model revealed a reduced risk of MACCEs associated with good adherence to CPAP (hazard ratio, 0.69 [95% CI, 0.52-0.92]).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 4186 individual participants were evaluated (82.1% men; mean [SD] body mass index, 28.9 [4.5]; mean [SD] age, 61.2 [8.7] years; mean [SD] apnea-hypopnea index, 31.2 [17] events per hour; 71% with hypertension; 50.1% receiving CPAP [mean {SD} adherence, 3.1 {2.4} hours per day]; 49.9% not receiving CPAP [usual care], mean [SD] follow-up, 3.25 [1.8] years).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Meta-analysis of randomized trials: PAP and cardiovascular events or death in sleep apnea
“The use of PAP, compared with no treatment or sham, was not associated with reduced risks of cardiovascular outcomes or death for patients with sleep apnea. Although there are other benefits of treatment with PAP for sleep apnea, these findings do not support treatment with PAP with a goal of prevention of these outcomes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Mean or median adherence to the intervention ranged between 1.4 hours per day and 6.6 hours per day.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adherence: nonadherence range across studies using a 4-hour nightly threshold
Adherence: CPAP nonadherence pooled across 20 years of trials, relative to a 7-hour night
“The overall CPAP non-adherence rate based on a 7-h/night sleep time that was reported in studies conducted over the twenty year time frame was 34.1 %. There was no significant improvement over the time frame.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adherence: 90-day adherence by the Medicare definition in a device manufacturer’s cloud database
“We assessed de-identified data from a large cloud database of positive airway pressure (PAP) users to examine adherence to therapy during the period 1-Oct-2014 to 31-Oct-2017.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All Air10 platform PAP devices (ResMed Inc., San Diego, USA) have an on-board mobile communications chip which connects to the secure cloud infrastructure automatically.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“ResMed Corp, USA funded the study and their employees (JA, AB, CMN) contributed to the design and conduct of the study, analysis, and interpretation of the data and preparation of the manuscript for publication.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary outcome was adherence, which was defined using the US Center for Medicare and Medicaid Services (CMS) definition (≥4 hours’ PAP use on 70% of nights in a consecutive 30-day period in the first 90 days of therapy).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The observed 90-day PAP adherence rate using the CMS definition was 75%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Prior studies suggest that up to 24% of patients may not fulfill their PAP prescription [14] and a proportion of patients may not even turn on their PAP machine.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Termination: CPAP termination at 1, 2, and 3 years in French national claims
“Therapy termination was defined as cessation of CPAP reimbursements.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 480,000 patients were included (mean age 59.3 ± 13.6 years, 65.4% male).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Overall CPAP termination rates after 1, 2 and 3 years were 23.1, 37.1 and 47.7%, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Therapy termination rates were highest in younger or older patients with ≥1 comorbidity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Persistence: five-year PAP persistence under telemonitoring and pay-for-performance in France
“A total of 84,550 patients (63.7% men, mean age 58.5 years, 53.6% with obesity, mean apnea-hypopnea index 40 events/h) were included; 95.7% used telemonitoring.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“PAP therapy persistence was 83.5% at 1 year, 68.4% at 3 years and 60.5% at 5 years.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Main documented reasons for stopping PAP were issues with PAP treatment (54.9%), changes in treatment needs (9.3%) and death (7.0%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“However, solutions are needed for patients who have PAP-related issues and to further reduce the therapy termination rate.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote